Publication: CpG DNA, liposome and refined antigen oral cholera vaccine
Issued Date
2003-12-01
Resource Type
ISSN
0125877X
Other identifier(s)
2-s2.0-2942564274
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Allergy and Immunology. Vol.21, No.4 (2003), 231-239
Suggested Citation
Ratree Leelawongtawon, Srinuan Somroop, Urai Chaisri, Pongsri Tongtawe, Manas Chongsa-nguan, Thareerat Kalambaheti, Pramuan Tapchaisri, Sathit Pichyangkul, Yuwaporn Sakolvaree, Hisao Kurazono, Hideo Hayashi, Wanpen Chaicumpa CpG DNA, liposome and refined antigen oral cholera vaccine. Asian Pacific Journal of Allergy and Immunology. Vol.21, No.4 (2003), 231-239. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/20868
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
CpG DNA, liposome and refined antigen oral cholera vaccine
Abstract
An oral cholera vaccine made up of three Vibrio cholerae antigens, i.e. lipopolysaccharide (LPS), recombinant toxin co-regulated pili (rTcpA) and heat-treated cholera toxin (H-CT) has been developed in six different formulations. Eight-week-old Wistar rats were divided into nine groups and immunized as follows: the first group received the oral vaccine 1 consisting of the three antigens (LPS, rTcpA and H-CT) associated with a liposome (L) and bacterial CpG-DNA (ODN#1826). The rats of groups 2 and 3 received oral vaccines 2 and 3 consisting of the liposome-associated three antigens with and without non-bacterial CpG-DNA (ODN#1982), respectively. Rats of groups 4 received oral vaccine 4 consisting of the three antigens mixed with the ODN#1826, similar to vaccine 1, but without liposome. Rats of groups 5 and 6 received oral vaccines 5 and 6 consisting of the three antigens with and without ODN#1982, respectively, similar to vaccines 2 and 3, but without liposome. Rats of groups 7, 8 and 9 received oral placebos, namely liposomes (L), ODN#1826 (CpG), and vaccine diluent, i.e. 5% NaHCO3solution, respectively. All vaccines were given in three doses at 14-day intervals. It was found that the combination of liposome and ODN#1826 in vaccine 1 evoked the highest immune response to V. cholerae antigen compared to other vaccine formulations and placebos, as measured by the appearance of antigen-specific antibody-producing cells in the intestinal lamina propria. The immunogenicity according to the magnitude of the immune response was: V1>V2=V3>V4>V5=V6>V7=V8=V9. The results of this study indicate that CpG-DNA and liposome are effective mucosal adjuvants for an oral cholera vaccine prepared from refined V. cholerae antigens and their combination seems to be synergistic. The potential role of liposome as a vaccine delivery vehicle has been confirmed.